Allergan’s €1.7 Billion Registered Fixed and Floating Rate Notes Offering

Cravath represented the underwriters, led by Barclays, Goldman Sachs & Co. LLC, J.P. Morgan Securities, Morgan Stanley, BNP Paribas, Bank of America Merrill Lynch, Citigroup, HSBC, Mizuho Securities and Mitsubishi UFJ Financial Group, in connection with the €1.7 billion registered fixed and floating rate notes offering of Allergan Funding SCS

Allergan Funding SCS is an indirect wholly owned subsidiary of Allergan plc, a global specialty pharmaceutical company.

Allergan plc, led by Brenton L Saunders, James C D’Arecca and Matthew M Walsh, in 2017 recorded $16 Billion Revenues.

Application has been made to the New York Stock Exchange.

The Cravath team included partner Andrew J. Pitts (Picture) and associates Mark Mushkin, Douglas C. Dolan, Tyler J. Cook and Charles A. Dobb.


Involved fees earner: Andrew Pitts – Cravath Swaine & Moore; Mark Mushkin – Cravath Swaine & Moore; Douglas Dolan – Cravath Swaine & Moore; Tyler Cook – Cravath Swaine & Moore; Charles Dobb – Cravath Swaine & Moore;

Law Firms: Cravath Swaine & Moore;

Clients: Barclays Bank; BNP Paribas; Bank of America Merrill Lynch; Citigroup Inc.; Goldman, Sachs & Co.; HSBC; Morgan Stanley; Mizuho Securities; JP Morgan Securities; Mitsubishi UFJ Financial Group;


Author: Ambrogio Visconti